Document is current
Any future updates will be listed below
-
Authors
Bansal, Radhika https://orcid.org/0000-0003-0964-098X
Baksh, Mizba
Larsen, Jeremy T.
Hathcock, Matthew A.
Dingli, David https://orcid.org/0000-0001-7477-3004
Stewart, A. Keith
Kapoor, Prashant https://orcid.org/0000-0002-4342-364X
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Hayman, Suzanne R.
Warsame, Rahma M.
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Ailawadhi, Sikander https://orcid.org/0000-0002-8377-8111
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
- License Information
-
More Information
Article History
Received: 13 September 2022
Revised: 14 March 2023
Accepted: 17 March 2023
First Online: 5 April 2023
Competing interests
: DD: Alexion, Novartis, Apellis, GSK, Sanofi, Janssen, PK: Sanodi, Pharmacyclics, BeiGene, Cellectar, Karyopharm, Abbvie, Takeda, Janssen, GlaxoSmithKline, Regeneron Pharmaceuticals, Ichnos Sciences, Amgen, RF: Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, OncoTracker SA: Bristol Myers Squibb, ADC Therapeutics, Seattle Genetics, Regeneron, Affimed, Al Therapeutics, Pfizer, Trillium and Takeda, GSK, Abbvie, Caris Life sciences, Adaptive biotechnologies, patent: prognostication of myeloma via FISH, SA: Beigene, SKK: BMS, Abbvie, Amgen, Takeda, Tenebio, Beigene, Oncopeptides, Antengene, Carsgen, Jannsen, KITE, Astra-zeneca, Novartis, Roche- Genentech, Bluebird Bio, YL: Kite, Janssen, Novartis, Celgene, Bluebird Bio, Juno, Legend, Sorrento, Gamida Cell, Vineti, Merck, Takeda. The remaining authors declare no competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in this manuscript.
